Product Details

Uniprot No.

Target Names

SUMO1

Alternative Names

DAP1 antibody; GAP modifying protein 1 antibody; GAP-modifying protein 1 antibody; GMP 1 antibody; GMP1 antibody; OFC10 antibody; PIC 1 antibody; PIC1 antibody; SENP2 antibody; Sentrin 1 antibody; Sentrin antibody; Small ubiquitin related modifier 1 antibody; Small ubiquitin-like modifier 1 antibody; Small ubiquitin-related modifier 1 antibody; SMT3 antibody; SMT3 homolog 3 antibody; SMT3 suppressor of mif two 3 homolog 1 antibody; SMT3, yeast, homolog 3 antibody; Smt3C antibody; SMT3H3 antibody; SUMO-1 antibody; SUMO1 antibody; SUMO1_HUMAN antibody; Ubiquitin homology domain protein PIC1 antibody; Ubiquitin Like 1 antibody; Ubiquitin like protein SMT3C antibody; Ubiquitin like protein UBL1 antibody; Ubiquitin-homology domain protein PIC1 antibody; Ubiquitin-like protein SMT3C antibody; Ubiquitin-like protein UBL1 antibody; UBL 1 antibody; UBL1 antibody

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human SUMO1

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

5G3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IHC, FC, IP

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
IP	1:200-1:1000

Protocols

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Flow Cytometry (FC) Protocol
Immunoprecipitation (IP) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

SUMO1 (Small ubiquitin-related modifier 1) plays a central role in post-translational modification pathways that regulate protein stability, nuclear transport, and transcriptional activity. SUMOylation—the covalent attachment of SUMO proteins to target substrates—influences diverse cellular processes including DNA repair, cell cycle progression, and stress responses, making SUMO1 a critical target for researchers investigating protein modification networks and their implications in disease states.

This recombinant monoclonal antibody, clone 5G3, offers the reproducibility and consistency that demanding experimental workflows require. Produced using recombinant technology with a sequence-defined rabbit IgG framework, it eliminates the lot-to-lot variability inherent in traditional hybridoma-derived antibodies, ensuring that your results remain comparable across extended studies and collaborative projects.

Validation data demonstrates robust performance across multiple applications. Immunohistochemistry staining in paraffin-embedded human tissues, including adrenal gland and liver cancer specimens, shows reliable detection using citrate buffer antigen retrieval on automated Leica Bond systems at dilutions around 1:92.5. For protein interaction studies, immunoprecipitation experiments successfully enriched SUMO1 from 293T whole cell lysates, confirming the antibody's utility for pulldown workflows. Flow cytometry analysis in HeLa cells, performed with ethanol fixation and Triton X-100 permeabilization, produced clear positive signal separation from control, supporting intracellular detection applications.

The antibody's affinity-purified format and compatibility with ELISA further extend its versatility for quantitative and screening approaches. Whether you are mapping SUMOylation dynamics in cancer biology, characterizing stress response pathways, or investigating nuclear protein trafficking, this antibody provides a dependable tool for advancing your cell biology research.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3.

Gene References into Functions

SUMO1 expression results in a gain of PKR activity by increasing its activation. SUMO1 was able to activate PKR and eIF-2alpha in the absence of viral infection. PMID: 29352251
SPOP inhibits hepatocellular carcinoma (HCC) cell metastasis via ubiquitin-dependent SUMO1/SENP7 proteolysis and may thus serve as a new opinion for the prevention of HCC metastasis. PMID: 29777712
Study found a significant difference in the expression of Cx43 and SUMO1 between cancer stem cells and non-cancer stem cells in liver cancer. By the co-expression of Cx43 and SUMO1 in cancer stem cells, the gap junction intercellular communication of liver cancer stem cells was obviously improved. PMID: 29393359
Two SUMO modification sites existed in dopamine receptor D1, the phosphorylation of which, due to SUMO modification, can interact with PP2A, leading to the inhibition of D1 de-phosphorylation and normal function. PMID: 28770955
These results suggest that SUMO1 contributes to hepatocellular carcinoma progression by promoting p65 nuclear translocation PMID: 26993772
In summary, our study revealed a negative regulation of the UPR transducer ATF6 through post-translational SUMOylation. The information from this study will not only increase our understanding of the fine-tuning regulation of the UPR signaling but will also be informative to the modulation of the UPR for therapeutic benefits. PMID: 29061306
Molecular dynamics simulations showed that binding of the beta-grasp domain of SUMO1 induces significant conformational and dynamic changes in SENP1, including widening of the exosite cleft and quenching of nanosecond dynamics in all but a distal region. PMID: 27576863
Mutational analysis of functional sites showed that both peroxidase and PLA2 active sites were necessary for mutant Prdx6 function, and that Prdx6 phosphorylation (at T177 residue) was essential for optimum PLA2 activity.Mutant Prdx6 at its Sumo1 sites escapes and abates this adverse process by maintaining its integrity and gaining function PMID: 28055018
SUMO and p21Cip1 regulate the transit of proteins through the nucleolus; disruption of nucleolar export by DNA damage induces SUMO and p21Cip1 to act as hub proteins to form a multiprotein complex in the nucleolus. PMID: 28582471
This study reveals an essential role of SUMOylated FADD in Drp1- and caspase-10-dependent necrosis. PMID: 27799292
SUMO-1 gene silencing inhibits proliferation and promotes apoptosis of human gastric cancer cells. PMID: 28222440
the critical role of Cys52 in maintaining SUMO-1 conformation and function PMID: 27195426
Findings suggest SUMO-1 protein and PGE2 receptor subtype 4 (EP4) as two potential targets for new therapeutic or prevention strategies for endometrial cancers. PMID: 27230680
This study demonstrated that the rs12472035 polymorphism of SUMO1 was significantly associated with an increased risk of AD in male group. PMID: 27084229
FOXP2 can be modified with all three human SUMO proteins and that PIAS1 promotes this process. PMID: 26867680
Ang II-induced upregulation of ATF3 and SUMO1 in vitro and in vivo was blocked by Ang II type I receptor antagonist olmesartan. Moreover, Ang II induced ATF3 SUMOylation at lysine 42, which is SUMO1 dependent. PMID: 26850942
Data show that mutation of key residues in the binding site abolishes binding and that small ubiquitin-like modifier 1 (SUMO1) can simultaneously and non-cooperatively bind both the ZZ domain and a canonical SIM motif of CREB-binding protein (CBP/p300). PMID: 27129204
Roles for SUMO in pre-mRNA processing PMID: 26563097
SUMOylation at specific sites on PXR protein are involved in enhancement of transcription function of this receptor. PMID: 26549688
High DAP1 expression is associated with a 4-fold increase in the risk of lymph node metastases in squamous cell carcinoma of the oral cavity. PMID: 26400283
Knockdown of SUMO1 using specific siRNA influenced the accumulation of lipid droplets and reduced HCV replication. PMID: 26449956
The LKB1 K178R SUMO mutant had defective AMPK signaling and mitochondrial function, inducing death in energy-deprived cells. PMID: 26212320
Data suggest that small ubiquitin-related modifier protein SUMO1 modification of the promyelocytic leukemia protein (PML) RING domain promotes SUMO2 conjugation to Lys160. PMID: 26060329
Data identify PDGFRbeta as the hub gene in both inflammatory (IBC) and non-inflammatory breast neoplasm (non-IBC) and SUMO1 and COL1A1 the respective key genes for IBC and non-IBC suggesting they might play important role in the pathogenesis of the neoplasm. PMID: 26403314
PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence. PMID: 26578773
Data indicate that small ubiquitin-like modifiers SUMO1, SUMO2, or SUMO3 were found in nuclear speckles. PMID: 26223657
These results confirm that the SUMO machinery is involved in TRIM5alpha-mediated retroviral restriction, and demonstrate that TRIM5alpha is a SUMO 1 and SUMO 2 substrate. PMID: 25880753
Under cell-free in vitro conditions, p35 is covalently modified by SUMO1. Sumoylation is a likely candidate mechanism for the rapid modulation of p35/Cdk5 activity in physiological situations as well as in disease. PMID: 25391294
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. PMID: 24953629
SUMO1 accelerates the accumulation of autophagic vacuoles and promotes Abeta production. PMID: 25484073
Expression of SUMO1/2/3 is dramatically enhanced by interferons through an miRNA-based mechanism involving the Lin28/let-7. PMID: 24942926
SUMO-1 modification may affect the transcriptional activity of EGFR PMID: 26244656
The crystal structures of SUMO1 bound to unphosphorylated and tetraphosphorylated PML-SUMO-interacting motifs peptides indicate that three phosphoserines directly contact specific positively charged residues of SUMO1. PMID: 25497731
The expression of SUMO-1 in OLP was similar to normal mucosa and inflammatory fibrous hyperplasia, suggesting that alterations of this protein occur at later stages of carcinogenesis PMID: 23350884
reveals an unexpected role of SUMO-1 and SAFB in the stimulatory coupling of promoter binding, transcription initiation and RNA processing PMID: 25800734
MDM2 and SUMO-1 proteins are up-regulated in actinic cheilitis and lip cancer. PMID: 25241153
Identify DRP1, RanGAP1 and topoisomerase IIa as targets of SUMO1 in human ejaculated sperm, giving more insights on the role of SUMO1-ylation in sperm morphology and motility. PMID: 25118297
findings provide empirical evidence that SUMO1 genetic polymorphisms might be strongly involved in the etiology of NSCL/P, especially for rs12470401 T>C, rs16838917 A>G, rs12470529 A>G, and rs7572505 A>G polymorphisms. PMID: 25111678
Overexpression of SUMO-1 decreased phosphorylated GSK-3beta at Ser-9. Mutagenesis of tau at K340R or inhibition of tau SUMOylation by ginkgolic acid abolishes the effect of SUMO-1. PMID: 25378699
The mutation of the sumoylation site (Lys137) of PTBP2 markedly inhibited its modification by SUMO1. PMID: 24286314
SUMO potentiates the inhibition of protein synthesis induced by PKR in response to dsRNA. PMID: 25074923
These results show that DAP1 is a key regulator, of the induction of apoptosis and reduction of autophagy by subtilase cytotoxin (SubAB). PMID: 25183729
identified 295 SUMO1 and 167 SUMO2 sites on endogenous substrates of HeLa cells PMID: 25114211
Modification of TDG by small ubiquitin-like modifier (SUMO) proteins weakens its binding to abasic DNA. PMID: 24753249
SUMO-1 modification of RARA is a potent mechanism for balancing proliferation and differentiation by controlling the stability of RARA in cancer cells. PMID: 24819975
SUMO1P3 was significantly up-regulated in gastric cancer tissues. PMID: 23996296
SUMO chain-induced dimerization activates RNF4. PMID: 24656128
The mitosis-dependent dynamic SUMO-1 modification of NuMA might contribute to NuMA-mediated formation and maintenance of mitotic spindle poles during mitosis. PMID: 24309115
PIASxalpha is a novel SUMO E3 ligase for PTEN, and it positively regulates PTEN protein level in tumor suppression. PMID: 24344134
SUMO participates in transcriptional repression as both a covalent modification and through non-covalent interactions with E2 and E3 enzymes. PMID: 24174529

Hide All

Involvement in disease

Non-syndromic orofacial cleft 10 (OFC10)

Subcellular Location

Nucleus membrane. Nucleus speckle. Cytoplasm. Nucleus, PML body. Cell membrane. Nucleus.

Protein Families

Ubiquitin family, SUMO subfamily

Database Links

HGNC: 12502

OMIM: 601912

KEGG: hsa:7341

STRING: 9606.ENSP00000376076

UniGene: Hs.81424

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA022948A0HU
Size	US$210
	Order now
Image	IHC image of CSB-RA022948A0HU diluted at 1:92.5 and staining in paraffin-embedded human adrenal gland tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system. IHC image of CSB-RA022948A0HU diluted at 1:92.5 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system. Immunoprecipitating SUMO1 in 293T whole cell lysate Lane 1: Rabbit control IgG instead of CSB-RA022948A0HU in 293T whole cell lysate. For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000) Lane 2: CSB-RA022948A0HU (3μg) + 293T whole cell lysate (500μg) Lane 3: 293T whole cell lysate (20μg) Overlay histogram showing Hela cells stained with CSB-RA022948A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then permeabilized with 0.3% Triton X-100 for 2 min. The cells were then incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4℃. The secondary antibody used was FITC goat anti-rabbit IgG (H+L) at 1/200 dilution for 1 h at 4℃. Control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

SUMO1 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background